Linked Life Data

8996570

Source:http://linkedlifedata.com/resource/pubmed/id/8996570

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
6 Suppl 13
pubmed:dateCreated
1997-2-4
pubmed:abstractText
Etoposide phosphate (Etopophos; Bristol-Myers Squibb Company, Princeton, NJ) is a water-soluble prodrug of etoposide that is converted in vivo by endogenous phosphatases to the active drug etoposide. This conversion process is efficient and not saturable in humans at doses between 50 and 1,600 mg/m2. The resultant etoposide demonstrates classic pharmacokinetics, and the etoposide phosphates dose is linearly related to peak levels and the area under the concentration-time curve of etoposide. The absence of noxious solvents and the ability to administer the drug in small volumes over short periods make etoposide a phosphate attractive for conventional- and high-dose clinical programs.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Dec
pubmed:issn
0093-7754
pubmed:author
pubmed:issnType
Print
pubmed:volume
23
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
8-14
pubmed:dateRevised
2007-11-15
pubmed:meshHeading
pubmed:year
1996
pubmed:articleTitle
Early studies of etoposide phosphate, a water-soluble prodrug.
pubmed:affiliation
Don Monti Division of Oncology, Department of Medicine, North Shore University Hospital, New York University School of Medicine, Manhasset, NY 11030, USA.
pubmed:publicationType
Journal Article, Review, Research Support, Non-U.S. Gov't